Form 4: Amgen SVP Rachna Khosla Reports Stock and Option Awards

Rachna Khosla, SVP of Business Development at Amgen, reports the acquisition of restricted stock units and non-qualified stock options.

Summary

• Rachna Khosla, a Senior Vice President at Amgen, filed a Form 4 detailing changes in beneficial ownership.
• On May 6, 2025, Khosla acquired 610 shares of common stock in the form of Restricted Stock Units (RSUs).
• These RSUs vest in four equal annual installments starting May 6, 2026.
• Vested RSUs will be paid in shares of Amgen's common stock on a one-to-one basis.
• Khosla also acquired 3,943 non-qualified stock options with an exercise price of $270.44.
• These options also vest in four equal annual installments commencing on May 6, 2026.
• The options expire on May 6, 2035.
• The report also mentions that Khosla holds 9,662 shares of common stock following the reported transactions, including 112 Dividend Equivalents (DEs).

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock and option grants, indicating a neutral sentiment.

Positives

• The grant of RSUs and stock options aligns Khosla's interests with those of Amgen's shareholders, incentivizing her to drive company performance.
• The vesting schedules of both the RSUs and stock options encourage long-term commitment from Khosla.

Future Outlook

The document does not contain specific forward-looking statements regarding Amgen's future performance, but the vesting schedules suggest an expectation of continued employment and contribution from Rachna Khosla.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates standard compensation practices for executives at publicly traded companies like Amgen.

Comparison to Industry Standards

• Equity compensation, including RSUs and stock options, is a common practice among large pharmaceutical companies like Amgen, Pfizer, and Johnson & Johnson.
• Vesting schedules of four years are also typical to retain key personnel.
• The specific amounts and terms of the grants would need to be compared to peer companies to determine if they are above or below industry averages for executives at Khosla's level.

Stakeholder Impact

• The stock and option grants align the executive's interests with shareholders, potentially driving long-term value creation.
• Employees may view the grants as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Form 4, Amgen, Rachna Khosla, Stock Options, Restricted Stock Units, Beneficial Ownership, Equity Incentive Plan